Veradermics MANE
NYSE MANE
$127.10 +4.82 (+3.94%)
As of: Oct 20, 2026 · 3:59 PM EDT

Veradermics (MANE) Enterprise Value (2026)

Updated

Veradermics' Enterprise Value was $4.32 billion in Q2 2026, up 313.9% from the prior quarter.

Analysis

Veradermics (MANE) Enterprise Value (2026) Analysis & Trends

On a trailing twelve-month basis, Veradermics' Enterprise Value was $3.73 billion through Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Veradermics 5.17 Bn 3.77 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.32 Bn
Mar 31, 2026 1.04 Bn
API Access

Veradermics Enterprise Value API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=enterprise-value&ticker=MANE&period=max&api_key=YOUR_API_KEY